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Protein tyrosine kinases have long been recognized
as the most proximal actors in T-cell antigen receptor
(TCR) signaling. Three non-receptor tyrosine kinase
families (Src, ZAP-70 and Tec) are known to be criti-
cal, but a new study now shows that room needs to
be made in this pathway for yet another protein tyro-
sine kinase family — Abl/Arg.
The ability of T cells to recognize and respond to infec-
tious agents is a key factor in mounting an adaptive
immune response, in which T and B cells work together
with other components of the immune system to elimi-
nate specific pathogens. Mature peripheral T cells rest
in the G0 phase of the cell cycle. For an adaptive
immune response to be initiated, T cells specific for the
infectious agent need to be induced to proliferate and
become activated. This signal is initiated by engage-
ment of the T-cell antigen receptor by its ligand, a
pathogen-derived antigenic peptide fragment pre-
sented to the T cell by an antigen-presenting cell.
Naturally, given the importance of the TCR in initiat-
ing T-cell activation, there has been intensive investi-
gation of the signaling pathways that are initiated in
response to TCR engagement. It was recognized as
early as the mid-1980s that the earliest biochemical
change that could be detected following engagement
of the TCR was the rapid accumulation of phospho-
tyrosine on numerous cellular proteins. The primacy of
protein tyrosine kinase activation in the TCR signaling
cascade was subsequently firmly established by phar-
macological, kinetic and genetic approaches, and
tyrosine kinases remain the prime movers in most TCR
signaling models [1].
None of the component polypeptide chains of the
TCR complex have intrinsic tyrosine kinase activity.
Instead, the TCR relies upon the recruitment of various
non-receptor tyrosine kinases into the microenviron-
ment of the activated TCR [1,2] (Figure 1). The Src-
family kinases, Lck and Fyn were the first tyrosine
kinases identified as playing a key role in TCR signaling.
Lck (and possibly Fyn) are involved in the earliest TCR-
initiated tyrosine phosphorylation events: the phospho-
rylation of tyrosine residues present within the
immunoreceptor tyrosine-based activation motifs
(ITAMs) present in each of the chains that make up the
CD3 signaling module of the TCR. Once phosphory-
lated, the ITAMs act as docking sites, recruiting ZAP-
70, via its tandem SH2 domains, to the activated TCR.
This recruitment of ZAP-70 to the TCR places ZAP-70
into proximity with activated Lck, which then phospho-
rylates and activates ZAP-70. This then allows ZAP-70
to act on downstream signaling molecules without
further regulation by other tyrosine kinases. Or so the
model has gone for the past decade [3]. The results of
Zipfel et al. [4] in this issue of Current Biology, however,
indicate that things are somewhat more complicated,
and that full ZAP-70 tyrosine phosphorylation and sig-
naling events downstream of ZAP-70 require the activ-
ity of Abl/Arg-family tyrosine kinases [4] (Figure 2).
Leaving aside for the moment the obvious impor-
tance of providing a better understanding of the early
events in TCR signaling, that this particular kinase,
which has been studied for over two decades, and was
one of the first proteins recognized to have tyrosine
kinase activity (along with Src), should find a home at
such a late date in such a well-studied signaling
pathway seems truly remarkable [5]. However, the first
clue that c-Abl might play a role in TCR signaling was
actually uncovered in 1991, when it was found that tar-
geted disruption of the Abl1 gene in mice resulted in
animals that had splenic and thymic atrophy and cell-
autonomous lymphopenia [6,7]. Perturbed T-cell mat-
uration, and the resultant lymphopenia, have been a
hallmark of disrupted expression of most of the pro-
teins identified as being critical components of the
TCR signaling pathway, including Lck, ZAP-70, and the
adaptor proteins LAT and SLP-76 [8].
What enabled these researchers to successfully
examine the role of Abl/Arg in TCR signaling was a
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Figure 1. Domain structure of tyrosine kinases involved in TCR
signaling.
The domain structures of the four tyrosine kinases that have
been implicated in TCR signaling are shown, as is the tyrosine
residue (Y) of ZAP-70 whose phosphorylation is regulated by
Abl/Arg. PH, pleckstrin homology; SH, Src homology; SH1, the
kinase domain; TH, Tec homology; PR, proline rich; NLS, nuclear
localization sequence; NES, nuclear exclusion sequence.
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potent combination of a selective endogenous marker
of Abl/Arg activity (phosphorylation of the downstream
target CrkL on Tyr207), an Abl/Arg-selective pharmaco-
logical inhibitor (STI-571, also known as Imatinib or
GleevecTM) and mice expressing various dosages of
Abl1 and Abl2 (the genes encoding Abl and Arg,
respectively). Having first established that TCR-stimu-
lated phosphorylation of CrkL at tyrosine 207 was
Abl/Arg-dependent (blocked by STI-571) and that Lck
and Syk (a more kinetically active ZAP-70 family
member) could not phosphorylate this residue in vitro,
Zipfel et al. [4] used an antibody specific for the phos-
phorylated Tyr207 residue of CrkL to track Abl/Arg
activity in situ, and found that TCR stimulation activated
Abl/Arg. This finding was confirmed in in vitro immune
complex kinase assays of plasma-membrane-bound
(but notably not cytosolic or nuclear) c-Abl [4].
Having established that c-Abl is activated following
TCR stimulation, delineation of where Abl/Arg fits into
the TCR signaling cascade was established by both
pharmacological and genetic approaches. STI-571 was
used to determine which signaling steps downstream
of TCR engagement were disrupted upon Abl/Arg inhi-
bition. Importantly, STI-571 does not inhibit members
of the Src and ZAP-70 family of tyrosine kinases [4,9].
Abl/Arg was found to act downstream of Lck, as STI-
571 had no effect on CD3ζ chain and overall ZAP-70
tyrosine phosphorylation, events which require Lck
activity. In addition, loss of Lck expression prevented
TCR-stimulated c-Abl activation, while loss of ZAP-70
expression had no effect. While overall ZAP-70 tyro-
sine phosphorylation, as measured by anti-phosphoty-
rosine western blotting, was unaffected by STI-571,
phosphorylation of Tyr319 of ZAP-70 was markedly
reduced, as was tyrosine phosphorylation of LAT and
SLP-76, two key ZAP-70 substrates [1,2]. Events
downstream of LAT phosphorylation, including the
recruitment of phospholipase C (PLC) γ1 to LAT, and
the subsequent tyrosine phosphorylation of PLCγ1,
and activation of the MAP kinase Erk were also defec-
tive in STI-571-treated T cells. In an elegant confirma-
tion of the inhibitor results, mouse T cells genetically
engineered to express Abl/Arg from only one of their
four alleles showed substantial inhibition in TCR sig-
naling to ZAP-70, LAT, PLCγ1 and Erk.
Thus, Abl/Arg would seem to act downstream of Lck
and upstream of ZAP-70, although it is not yet clear
whether Abl/Arg acts exclusively through ZAP-70, or
whether it might directly target other TCR signaling
proteins downstream of ZAP-70. For LAT phosphory-
lation in particular, ZAP-70 seems to be a required
intermediary of c-Abl, as TCR stimulation did not cause
LAT phosphorylation in the absence of ZAP-70 [10–12].
It is also not yet clear whether c-Abl acts by augment-
ing ZAP-70 activity per se (Tyr319 has long been con-
sidered to be a site of autophosphorylation [10,13,14])
or whether c-Abl directly phosphorylates this residue
and thereby affects the ability of ZAP-70 to interact
with other proteins. Relevant to this latter possibility,
Tyr319 has been found to serve as a binding site for
Lck and PLCγ1 [10,15], and lies within a consensus
binding site for the SH2 domain of Crk family proteins
[16] and of Abl itself [5].
As would be expected in response to inhibition of the
ZAP-70–LAT–SLP-76 signaling axis, STI-571 inhibition
of Abl/Arg activity (or reduction in Abl/Arg gene dosage)
also inhibited more distal TCR signaling events, includ-
ing activation of the interleukin-2 (IL-2) gene promoter,
IL-2 secretion and cell proliferation [4]. These results
would predict that STI-571 has the potential to act as
an immunosuppressant. This prediction has been borne
out by recent reports of reactivation of latent
Epstein–Barr and Varicella–Zoster viral infections in a
subset of chronic myelogenous leukemia patients
receiving treatment with STI-571 [17,18], providing elo-
quent testament to the significance of adding Abl/Arg
to the cadre of TCR-activated tyrosine kinases, and of
the importance of further delineating the mechanism by
which Abl/Arg participates in TCR signaling.
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Figure 2. Placement of Abl/Arg in the TCR signaling pathway.
Depicted are the early signaling events that lead to the forma-
tion of the multi-molecular ‘signalosome’ complex that forms in
response to tyrosine phosphorylation of LAT and SLP-76. For
graphical clarity the participation of the small molecular weight
adaptor proteins Grb2 and Gads in the formation of the
complex is not shown.
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